PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Outlook Therapeutics Inc | OTLK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.02 | -1.77% | 1.11 | 1.13 | 1.11 | 1.13 | 1.13 | 09:44:33 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.11 | 1.12 | 0.01 | 0.89% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 32 | 15,396 | $ 1.11 | $ 17,154 | 521,173 | 0.85 - 20.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:44:33 | 100 | $ 1.11 | USD |
Outlook Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 31.34M | 28.23M | $ -30.09M | -10.24 | - | 20.05M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 13.00 | 29.00% |
Outlook Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/06/2019 | 17:16 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/15/2019 | 17:08 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) |
| 10/07/2019 | 18:12 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:10 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:08 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.36 | 1.37 | 1.0704 | 1.15 | 649,862 | -0.25 | -18.38% |
| 1 Month | 1.13 | 1.74 | 0.95 | 1.36 | 748,531 | -0.02 | -1.77% |
| 3 Months | 1.63 | 1.76 | 0.95 | 1.36 | 324,911 | -0.52 | -31.9% |
| 6 Months | 1.92 | 2.89 | 0.95 | 2.07 | 612,287 | -0.81 | -42.19% |
| 1 Year | 3.248 | 20.00 | 0.85 | 2.51 | 1,574,851 | -2.14 | -65.83% |
| 3 Years | 5.60 | 20.00 | 0.85 | 2.51 | 1,544,622 | -4.49 | -80.18% |
| 5 Years | 5.60 | 20.00 | 0.85 | 2.51 | 1,544,622 | -4.49 | -80.18% |
Outlook Therapeutics Description
| Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. |
